3-(cyclohexyloxy)-1-propanol methanesulfonate (ester) | 823226-18-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 3-(cyclohexyloxy)-1-propanol methanesulfonate (ester)
• 英文别名: 3-(Cyclohexyloxy)-1-propanol methanesulfonate；3-cyclohexyloxypropyl methanesulfonate
• CAS: 823226-18-2
• 化学式: C₁₀H₂₀O₄S
• 分子量: 236.332
• InChiKey: HLIGAYDMLTYQGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(cyclohexyloxy)-1-propanol methanesulfonate (ester) 在 sodium azide 、 水 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(环己氧基)丙胺
  参考文献：
  名称：

  Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds

  摘要：

  A novel series of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA(2) receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (14) with K-d = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, "shunt" effect to elevate PGI(2) level, and absence of agonist activity.

  DOI：

  10.1021/jm980173n
• 作为产物：
  描述：

  3-(cyclohexyloxy)propionic acid 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-(cyclohexyloxy)-1-propanol methanesulfonate (ester)
  参考文献：
  名称：

  Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds

  摘要：

  A novel series of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA(2) receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (14) with K-d = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, "shunt" effect to elevate PGI(2) level, and absence of agonist activity.

  DOI：

  10.1021/jm980173n

文献信息

• [EN] 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS<br/>[FR] 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES SERVANT D'ANTAGONISTES DE 5HT4
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005000838A1

  公开（公告）日：2005-01-06

  The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.

  本发明涉及具有5HT4拮抗性质的式(I)的新化合物。该发明还涉及制备这种新化合物的方法，包括将该新化合物作为药物的药物组合物以及该化合物的药用用途。
• .sigma. Ligands with Subnanomolar Affinity and Preference for the .sigma.2 Binding Site. 2. Spiro-Joined Benzofuran, Isobenzofuran, and Benzopyran Piperidines
  作者：Ejner K. Moltzen、Jens Perregaard、Eddi Meier

  DOI：10.1021/jm00011a020

  日期：1995.5

  structural factors governing sigma 1/sigma 2 affinity and selectivity within this class of compounds. The N-substituent in spiro[isobenzofuran-1(3H),4'-piperidines] is highly important, both for affinity and selectivity. Spiropiperidines with no or small N-substituents (H, Me, Et) exert very low affinity for both sigma 1 and sigma 2 binding sites (IC50(sigma 1, sigma 2) > 100 nM), whereas medium-sized substituents

  合成了螺[异苯并呋喃-1（3H），4'-哌啶]及相应的苯并呋喃和苯并吡喃衍生物，并作为σ配体进行了评估。这些化合物与Lu 28-179（1'-[4- [1-（4-氟苯基）-1H-吲哚-3-基] -1-丁基]螺[异苯并呋喃-1（3H），4'-哌啶]已被证明是选择性的sigma 2配体，其亲和力在亚纳摩尔范围内。该研究的目的是确定在这类化合物中控制sigma 1 / sigma 2亲和力和选择性的结构因素。螺[异苯并呋喃-1（3H），4'-哌啶]中的N-取代基对于亲和力和选择性都非常重要。没有或只有少量N取代基（H，Me，Et）的螺哌啶对sigma 1和sigma 2结合位点都具有非常低的亲和力（IC50（sigma 1，sigma 2）> 100 nM），而中等大小的取代基（例如Pr，Bu，Ph（CH2）2）会产生有效但非选择性的化合物（IC50（sigma 1，sigma 2）= 2-5
• N-(4-piperodinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05185335A1

  公开（公告）日：1993-02-09

  Piperidine derivatives of formula ##STR1## wherein A is a radical of formula ##STR2## wherein one or two hydrogen atoms in said radicals (a-1) to (a-3) may be replaced by a C.sub.1-6 alkyl radical; R.sup.1 is hydrogen or halo; R.sup.2 is hydrogen, amino, mono or di(C.sub.1-6 alkyl)amino or C.sub.1-6 alkylcarbonylamino; R.sup.3 is hydrogen or C.sub.1-6 alkyl; L is C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, C.sub.3-6 alkenyl optionally substituted with aryl, or L is a radical of formula ##STR3## the N-oxide forms, addition salts and stereochemically isomeric forms thereof, said compounds having gastrointestinal motility stimulating properties. Pharmaceutical compositions containing these compounds as active ingredient, and a method of preparing said compounds and pharmaceutical compositions.

  本发明涉及一种式子为##STR1##的哌啶衍生物，其中A是式子##STR2##的基团，其中在所述基团(a-1)到(a-3)中的一个或两个氢原子可以被C.sub.1-6烷基基团取代；R.sup.1是氢或卤素；R.sup.2是氢，氨基，单或双(C.sub.1-6烷基)氨基或C.sub.1-6烷基羰基氨基；R.sup.3是氢或C.sub.1-6烷基；L是C.sub.3-6环烷基，C.sub.5-6环己酮，C.sub.3-6烯基（可以选择地用芳基取代），或L是式子##STR3##的基团，其N-氧化物形式，加成盐和立体化学异构体形式，这些化合物具有促进胃肠动力的特性。本发明还涉及以这些化合物为活性成分的制药组合物，以及制备这些化合物和制药组合物的方法。
• N-(4-piperidinyl) (dihydroxybenzofuran or
  申请人：Tanssen Pharmaceutica N.V.

  公开号：US05262418A1

  公开（公告）日：1993-11-16

  Piperidine derivatives of formula ##STR1## wherein A is a radical of formula --CH.sub.2 --CH.sub.2 -- (a-1), --CH.sub.2 --CH.sub.2 --CH.sub.2 -- (a-2), or --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 -- (a-3), wherein one or two hydrogen atoms in said radicals (a-1) to (a-3) may be replaced by a C.sub.1-6 alkyl radical; R.sup.1 is hydrogen or halo; R.sup.2 is hydrogen, amino, mono or di(C.sub.1-6 alkyl)amino or C.sub.1-6 alkylcarbonylamino; R.sup.3 is hydrogen or C.sub.1-6 alkyl; L is C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, C.sub.3-6 alkenyl optionally substituted with aryl, or L is a radical of formula --Alk--R.sup.4 (b-1), --Alk--X--R.sup.5 (b-2), --Alk--Y--C(.dbd.O)--R.sup.7 (b-3), or --Alk--Y--C(.dbd.O)--NR.sup.9 R.sup.10 (b-4), the N-oxide forms, addition salts and stereochemically isomeric forms thereof, said compounds having gastrointestinal motility stimulating properties. Pharmaceutical compositions containing these compounds as active ingredient, and a method of preparing said compounds and pharmaceutical compositions.

  式为##STR1##的哌啶衍生物，其中A是式--CH.sub.2 --CH.sub.2 -- (a-1)、--CH.sub.2 --CH.sub.2 --CH.sub.2 -- (a-2)或--CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 -- (a-3)的基团，其中在所述基团(a-1)到(a-3)中的一个或两个氢原子可以被C.sub.1-6烷基基团取代；R.sup.1是氢或卤素；R.sup.2是氢、氨基、单或双(C.sub.1-6烷基)氨基或C.sub.1-6烷基羰基氨基；R.sup.3是氢或C.sub.1-6烷基；L是C.sub.3-6环烷基、C.sub.5-6环戊酮、C.sub.3-6烯基（可选择用芳基取代）或式--Alk--R.sup.4 (b-1)、--Alk--X--R.sup.5 (b-2)、--Alk--Y--C(.dbd.O)--R.sup.7 (b-3)或--Alk--Y--C(.dbd.O)--NR.sup.9 R.sup.10 (b-4)的基团，其N-氧化物形式、加成盐和立体化学异构体，这些化合物具有胃肠动力促进作用。含有这些化合物作为活性成分的制药组合物以及制备这些化合物和制药组合物的方法。
• N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0445862A2

  公开（公告）日：1991-09-11

  Piperidine derivatives of formula wherein A is a radical of formula         -CH₂-CH₂-   (a-1),         -CH₂-CH₂-CH₂-   (a-2), or         -CH₂-CH₂-CH₂-CH₂-   (a-3), wherein one or two hydrogen atoms in said radicals (a-1) to (a-3) may be replaced by a C₁₋₆alkyl radical;    R¹ is hydrogen or halo; R² is hydrogen, amino, mono or di(C₁₋₆alkyl)amino or C₁₋₆alkylcarbonylamino; R³ is hydrogen or C₁₋₆alkyl; L is C₃₋₆cycloalkyl, C₅₋₆cycloalkanone, C₃₋₆alkenyl optionally substituted with aryl, or L is a radical of formula         -Alk-R⁴   (b-1),         -Alk-X-R⁵   (b-2),         -Alk-Y-C(=O)-R⁷   (b-3), or         -Alk-Y-C(=O)-NR⁹R¹⁰   (b-4), the N-oxide forms, addition salts and stereochemically isomeric forms thereof, said compounds having gastrointestinal motility stimulating properties. Pharmaceutical compositions containing these compounds as active ingredient, and a method of preparing said compounds and pharmaceutical compositions.

  式中的哌啶衍生物 其中 A 是式中的基团 -CH₂-CH₂-(a-1)、 -CH₂-CH₂-CH₂-（a-2），或 -CH₂-CH₂-CH₂-CH₂-（a-3）、 其中，(a-1)至(a-3)中的一个或两个氢原子可被 C₁₋₆ 烷基取代； R¹ 是氢或卤代；R² 是氢、氨基、一或二(C₁₋₆烷基)氨基或 C₁₋₆烷基羰基氨基；R³ 是氢或 C₁₋₆烷基；L是C₃₋₆环烷基、C₅₋₆环烷酮、任选被芳基取代的C₃₋₆烯基，或者L是式中的自由基 -Alk-R⁴ (b-1)、 -Alk-X-R⁵（b-2）、 -Alk-Y-C(=O)-R⁷（b-3），或 -Alk-Y-C(=O)-NR⁹R¹⁰（b-4）、 N-氧化物形式、加成盐及其立体异构形式，所述化合物具有刺激胃肠道蠕动的特性。含有这些化合物作为活性成分的药物组合物，以及制备所述化合物和药物组合物的方法。